Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the startup of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University. Follow Rob on Twitter @rob_cyran
- Tel: +1 646 223 6083
- E-mail: firstname.lastname@example.org
Cigna and Anthem haven’t consummated their merger, yet the U.S. insurers are squabbling over a lawsuit, information sharing and executives’ roles. The disharmony could make the deal fall apart. At the very least, it will make it harder to push it past antitrust regulators.
Sales at the likes of Qualcomm are falling for a second year in a row. Tight buyers in an unsettled global economy are partly to blame, but the semiconductor industry also lacks whiz-bang products. After a similar downturn during the financial crisis, the prognosis may be grim.
Microsoft finally ditched the basic handset business in a deal that will see the devices reborn under the control of former Nokia bosses and Foxconn. The $350 mln sale price for the former crown jewel of a $300 bln enterprise is a testament to how quickly tech empires can vanish.
- Dell, Dex sum up dozy bondholders in a nutshell
- Apple falls far from Buffett's investing tree
- Facebook better off liking title of top media firm
- Dish short fund has investor appeal – at a price
- From Allergan to Zoetis: new drug M&A perspectives
- Pfizer mulls actually having an M&A strategy
- Medical firms' $18 bln merger lacks clear logic